BridgeBios Pipeline Expansion Continues as Portfolios Milestones Approach

▤ Summary

BBP-303 is a good example of how BridgeBio’s model works, Turtle said, because it’s a drug that previously was developed unsuccessfully for osteoporosis but was identified as a potential treatment for ADH1 by the National Institutes of Health (NIH). It was hypothesized to be sufficient to treat osteoporosis, but unfortunately it wasn’t.” However, the NIH believes that for ADH1 —which is caused by mutations in the calcium-sensing receptor that results in hypocalcemia, or low serum calcium levels—BBP-303’s mechanism matches the need in this disease. This approach lets us work with academic collaborators around the world and identify a really tractable drug starting point and put together programs in a quick way and move them forward.” Turtle said BridgeBio executives frequently are asked, ‘Don’t you have a huge pipeline already?’ But he noted that when the company compares its pipeline to the number of diseases with unmet needs, “I think we’re just getting started.” BridgeBio has different strategies for taking on different drug candidates, however, based on the size of a disease’s market and the stage of the potential treatment. “We most often start from an idea that an academic has or at best a dirty lead molecule or an approach that looks like it’s having some level of efficacy, but certainly it’s not a final drug candidate—something that you could put into the clinic.” “The other thing that matters is what the potential registration path looks like,” he added. “So, I think that the dynamic has shifted quite a bit, where a few years ago we were the ones walking down the hallways of children’s hospitals knocking on doors trying to get people to give us some time and chat about putting together a company,” he said.

▦ Linked Companies

Shareaholic

$1M to $5M